Guild discovered a vascular structure at the jugular vein bulb and middle ear promontory in 1941, and named it glomus body. The glomus jugulare tumor was first reported by Rossenwasser in 1945 and was named carotid body-like tumor at that time, and many similar reports followed, but the names were not uniform, including bulbar tumor, non-chromophilic paraganglioma, chemoreceptor tumor, and angioblastoma. Winship later renamed it as jugular venous bullae tumor, which led to the general acceptance of this name. Nowadays, studies have confirmed that this tumor is a paraganglioma, so it should be named as paraganglioma, but the name jugular globoid tumor is still commonly used because of the habit. The paraganglioma of the temporal bone lacks histological staining affinity for chromium salts and has no definite role in the neuroendocrine system, and is therefore also referred to as a non-chromophilic paraganglioma. Adult temporal bones usually have only two to three paraganglia, but sometimes more. Most temporal bone paraganglia are located in the anterolateral region of the jugular fossa and in the middle ear, so tumors originating in the paraganglia also occur mainly in these two areas, and those originating in the middle ear are called tympanic bullae tumors, and those originating in the jugular fossa are called jugular vein bullae tumors. The incidence of jugular vein bulb tumor is low. According to Lack, there were 69 cases of head and neck bulb tumor among 600,000 people, of which only 8 cases were jugular vein bulb tumor, with an incidence rate of 0.012%. However, jugular vein bullae tumor is the most common tumor originating in the middle ear and the most common type of pathology involving the jugular foramen. It is more common in women, with a male to female ratio of approximately 6:1, and can be seen at any time from infancy to old age, but the high incidence is between 50 and 60 years of age. The younger the age of onset, the more rapidly the tumor develops and the more likely it is to be multifocal and vasoactive substance secreting. Approximately 5% of patients may have multisite tumors, but this percentage can be as high as 50% if the patient has a family history of the disease. Although paragangliomas have catecholamine-containing neurosecretory granules, only 1-3% of tumors actually secrete norepinephrine, with a higher percentage secreted by jugular venous bulbar tumors than by bulbar bulbar tumors. It is controversial whether screening for temporal paraganglioma is necessary to understand its function, but patients with a history of facial flushing, frequent diarrhea, palpitations, headache, uncontrollable hypertension, orthostasis, or excessive sweating should be screened for serum catecholamines as well as 24-hour urinary vanilloid acid and methanephrine levels.